Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)

NCT00943072 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

189

Enrollment

INDUSTRY

Sponsor class

Conditions

Macular Edema Secondary to Central Retinal Vein Occlusion

Interventions

BIOLOGICAL: VEGF Trap-Eye 2.0mg
DRUG: Sham

Sponsor

Regeneron Pharmaceuticals

Collaborators

[object Object]